| Drug Name |
Gilteritinib |
| Drug ID |
BADD_D02505 |
| Description |
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830] |
| Indications and Usage |
Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an FLT3 mutation detected by an FDA-approved test. This indication was expanded for a companion diagnostic to include use with gilteritinib such as the LeukoStrat CDx FLT3 Mutation Assay.[L4830]
Acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of continuous need for transfusions.[L4832] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EX13 |
| DrugBank ID |
DB12141
|
| KEGG ID |
D10709
|
| MeSH ID |
C000609080
|
| PubChem ID |
49803313
|
| TTD Drug ID |
D04KZY
|
| NDC Product Code |
0469-1425 |
| UNII |
66D92MGC8M
|
| Synonyms |
gilteritinib | ASP-2215 | ASP2215 | Xospata |
